Modality
ASO
MOA
CAR-T BCMA
Target
EZH2
Pathway
Epigenetic
RACKD
Development Pipeline
Preclinical
~Aug 2012
→ ~Nov 2013
Phase 1
~Feb 2014
→ ~May 2015
Phase 2
~Aug 2015
→ ~Nov 2016
Phase 3
Feb 2017
→ Aug 2031
Phase 3Current
NCT05964785
205 pts·CKD
2021-11→2031-08·Completed
NCT06342661
1,636 pts·RA
2017-06→2026-08·Not yet recruiting
NCT03189432
2,043 pts·CKD
2017-02→2030-02·Recruiting
+1 more trial
4,280 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2026-08-265mo awayPh3 Readout· RA
2030-02-243.9y awayPh3 Readout· CKD
2031-04-035.0y awayPh3 Readout· CKD
2031-08-065.3y awayPh3 Readout· CKD
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Recruit…
P3
Not yet…
P3
Complet…
P3
Active
Catalysts
Ph3 Readout
2026-08-26 · 5mo away
RA
Ph3 Readout
2030-02-24 · 3.9y away
CKD
Ph3 Readout
2031-04-03 · 5.0y away
CKD
Ph3 Readout
2031-08-06 · 5.3y away
CKD
RecruitingActiveCompletedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05964785 | Phase 3 | CKD | Completed | 205 | EFS |
| NCT06342661 | Phase 3 | RA | Not yet recr... | 1636 | PANSS |
| NCT03189432 | Phase 3 | CKD | Recruiting | 2043 | PANSS |
| NCT05443237 | Phase 3 | CKD | Active | 396 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| ACA-2691 | Acadia Pharma | Phase 3 | BCMA | |
| Olpasotorasib | Structure Ther | Preclinical | C5 | |
| AGI-4446 | Agios | Phase 3 | PSMA |